Emerging Data and Evidence for Dual Immunotherapy plus Chemotherapy in First-Line mNSCLC

Video content above is prompted by the following:

• How do mutations associated like STK11, KEAP1, KRAS impact effectiveness of standard therapies and confer resistance? 

• In real-world clinical practice, how frequently do patients with mNSCLC undergo comprehensive molecular and biomarker testing through techniques like NGS to evaluate for genetic alterations and potential targetable mutations?